Molecular underpinnings of enzalutamide resistance

S. Prekovic, T. van den Broeck, S. Linder, M. E. van Royen, A. B. Houtsmuller, F. Handle, S. Joniau, W. Zwart, F. Claessens

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

3 Citaties (Scopus)

Uittreksel

Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer.

TaalEngels
Pagina'sR545-R557
Aantal pagina's13
TijdschriftEndocrine-related cancer
Volume25
Nummer van het tijdschrift11
DOI's
StatusGepubliceerd - 1 nov 2018

Vingerafdruk

Prostatic Neoplasms
Androgen Receptors
Second Primary Neoplasms
Therapeutics
Hormones
Survival
Research
MDV 3100
Neoplasms

Trefwoorden

    Citeer dit

    Prekovic, S., van den Broeck, T., Linder, S., van Royen, M. E., Houtsmuller, A. B., Handle, F., ... Claessens, F. (2018). Molecular underpinnings of enzalutamide resistance. Endocrine-related cancer, 25(11), R545-R557. DOI: 10.1530/ERC-17-0136
    Prekovic, S. ; van den Broeck, T. ; Linder, S. ; van Royen, M. E. ; Houtsmuller, A. B. ; Handle, F. ; Joniau, S. ; Zwart, W. ; Claessens, F./ Molecular underpinnings of enzalutamide resistance. In: Endocrine-related cancer. 2018 ; Vol. 25, Nr. 11. blz. R545-R557
    @article{38e184482a8d42c4a427e2fe6372045e,
    title = "Molecular underpinnings of enzalutamide resistance",
    abstract = "Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer.",
    keywords = "abiraterone, AKR3C1, androgen receptor, autophagy, cancer, enzalutamide, glycolysis, hexosamine biosynthesis, IL-6, mCRPC, mutations, prostate cancer, resistance, Wnt",
    author = "S. Prekovic and {van den Broeck}, T. and S. Linder and {van Royen}, {M. E.} and Houtsmuller, {A. B.} and F. Handle and S. Joniau and W. Zwart and F. Claessens",
    year = "2018",
    month = "11",
    day = "1",
    doi = "10.1530/ERC-17-0136",
    language = "English",
    volume = "25",
    pages = "R545--R557",
    journal = "Endocrine-related cancer",
    issn = "1351-0088",
    publisher = "BioScientifica Ltd.",
    number = "11",

    }

    Prekovic, S, van den Broeck, T, Linder, S, van Royen, ME, Houtsmuller, AB, Handle, F, Joniau, S, Zwart, W & Claessens, F 2018, 'Molecular underpinnings of enzalutamide resistance' Endocrine-related cancer, vol. 25, nr. 11, blz. R545-R557. DOI: 10.1530/ERC-17-0136

    Molecular underpinnings of enzalutamide resistance. / Prekovic, S.; van den Broeck, T.; Linder, S.; van Royen, M. E.; Houtsmuller, A. B.; Handle, F.; Joniau, S.; Zwart, W.; Claessens, F.

    In: Endocrine-related cancer, Vol. 25, Nr. 11, 01.11.2018, blz. R545-R557.

    Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademicpeer review

    TY - JOUR

    T1 - Molecular underpinnings of enzalutamide resistance

    AU - Prekovic,S.

    AU - van den Broeck,T.

    AU - Linder,S.

    AU - van Royen,M. E.

    AU - Houtsmuller,A. B.

    AU - Handle,F.

    AU - Joniau,S.

    AU - Zwart,W.

    AU - Claessens,F.

    PY - 2018/11/1

    Y1 - 2018/11/1

    N2 - Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer.

    AB - Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer.

    KW - abiraterone

    KW - AKR3C1

    KW - androgen receptor

    KW - autophagy

    KW - cancer

    KW - enzalutamide

    KW - glycolysis

    KW - hexosamine biosynthesis

    KW - IL-6

    KW - mCRPC

    KW - mutations

    KW - prostate cancer

    KW - resistance

    KW - Wnt

    UR - http://www.scopus.com/inward/record.url?scp=85054779421&partnerID=8YFLogxK

    U2 - 10.1530/ERC-17-0136

    DO - 10.1530/ERC-17-0136

    M3 - Article

    VL - 25

    SP - R545-R557

    JO - Endocrine-related cancer

    T2 - Endocrine-related cancer

    JF - Endocrine-related cancer

    SN - 1351-0088

    IS - 11

    ER -

    Prekovic S, van den Broeck T, Linder S, van Royen ME, Houtsmuller AB, Handle F et al. Molecular underpinnings of enzalutamide resistance. Endocrine-related cancer. 2018 nov 1;25(11):R545-R557. Beschikbaar vanaf, DOI: 10.1530/ERC-17-0136